Revvity, formerly known as PerkinElmer, has been drawing significant attention in the biotech sector. Significant positions within Revvity have been acquired by numerous renowned banks including the Amalgamated Bank, National Pension Service, Swiss National Bank, Alabama's Retirement Systems, and Truist Financial Corp, demonstrating growing institutional trust. The company's performance won over analysts, meeting Q1 earnings and revenue estimates, in addition to having a robust autoimmune diagnostics system. The price target for Revvity has been lifted by TD Cowen and Robert W. Baird due to its steady performance. However, shareholders have experienced a decline in the past, likely due to earnings drop. The company has launched innovations like single solution for drug development and advances in Tuberculosis testing, and it's primarily controlled by institutional shareholders who own approximately 80% of the firm. They have announced dividends from their board on a quarterly basis, signifying a strong return on capital. Despite the indicators of solid fundamentals, there have been periods of stock price weakness. Recently a complaint was filed against Cloud Software group and Revvity is seeking injunctive relief.
Revvity RVTY News Analytics from Mon, 26 Jul 2021 07:00:00 GMT to Fri, 10 May 2024 10:07:37 GMT -
Rating 6
- Innovation 8
- Information 6
- Rumor -2
